Top Banner Top Banner

Clinical Trials
Ongoing Clinical Trials
Please select a trial to learn more

Recruiting
Temozolomide and Radiation Therapy With or Without Bevacizumab in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab, Drug: temozolomide, Other: placebo
Phase: Phase III
Recruiting
Trial of Enzastaurin and Bevacizumab in Adults With Recurrent Malignant Gliomas
Conditions: Recurrent Glioblastoma
Interventions: Drug: enzastaurin, Drug: bevacizumab
Phase: Phase II
Recruiting
Valproic Acid and Radiation Followed by Maintenance Valproic Acid and Bevacizumab in Children With High Grade Gliomas
Conditions: Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma
Interventions: Drug: Valproic acid, Drug: Bevacizumab, Radiation: Radiation therapy
Phase: Phase II
Recruiting
Bi-weekly Temozolomide Plus Bevacizumab for Adult Patients With Recurrent Glioblastoma Multiforme
Conditions: Recurrent Glioblastoma Multiforme, Recurrent Gliosarcoma
Interventions: Drug: temozolomide and bevacizumab
Phase: Phase II
Recruiting
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Conditions: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3, Biological: ramucirumab
Phase: Phase II
Recruiting
A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Conditions: Glioblastoma, Astrocytoma
Interventions: Drug: Bevacizumab/Irinotecan
Phase: Phase II
Recruiting
Sunitinib to Treat Recurrent Brain Cancer
Conditions: Glioblastoma Multiforme, Malignant Gliomas, Anaplastic Gliomas
Interventions: Drug: Sutent (sunitinib)
Phase: Phase II
Recruiting
A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma
Conditions: Glioblastoma Multiforme
Interventions: Drug: bevacizumab [Avastin], Drug: irinotecan, Drug: temozolomide
Phase: Phase II
Recruiting
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
Conditions: Glioblastoma Multiforme, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Mixed Oligoastrocytoma
Interventions: Drug: ZD6474, Drug: Carboplatin
Phase: Phase II
Recruiting
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate, Drug: temozolomide, Other: placebo, Radiation: 3-dimensional conformal radiation therapy, Radiation: intensity-modulated radiation therapy
Phase: Phase II
Recruiting
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Conditions: Brain Cancer, Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab, Drug: Low Dose Bevacizumab, Drug: Lomustine
Phase: Phase II
Recruiting
Neo-adjuvant Treatment With Temozolomide and Bevacizumab Previous to Temozolomide Plus Radiation Plus Bevacizumab Therapy in Unresectable Glioblastoma
Conditions: Glioblastomas
Interventions: Drug: Temozolomide, Drug: Bevacizumab, Radiation: Standard radiation therapy
Phase: Phase II
Recruiting
AMG 102 and Avastin for Recurrent Malignant Glioma
Conditions: Grade IV Malignant Glioma, Glioblastoma Multiforme, Gliosarcoma
Interventions: Drug: AMG 102 plus Avastin (bevacizumab)
Phase: Phase II
Recruiting
RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Interventions: Drug: gamma-secretase inhibitor RO4929097, Other: laboratory biomarker analysis, Other: pharmacological study, Procedure: adjuvant therapy, Procedure: neoadjuvant therapy, Procedure: therapeutic conventional surgery
Phase: Phase II
Recruiting
Temozolomide and Procarbazine With Cilengitide for Patients With Glioblastoma Multiforme Without Methylation of the MGMT Promoter Gene
Conditions: Newly Diagnosed Non Methylated Glioblastoma Multiforme Grade 4
Interventions: Drug: Cilengitide
Phase: Phase II
Recruiting
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Conditions: Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
Interventions: Biological: bevacizumab, Drug: temozolomide, Other: laboratory biomarker analysis, Other: immunohistochemistry staining method, Genetic: microarray analysis, Genetic: DNA methylation analysis
Phase: Phase II
Recruiting
Temozolomide With or Without Bevacizumab in Treating Patients With Recurrent Glioma
Conditions: Brain and Central Nervous System Tumors
Interventions: Biological: bevacizumab, Drug: temozolomide, Other: laboratory biomarker analysis
Phase: Phase II
Recruiting
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Conditions: Glioblastoma Multiforme, Gliosarcoma, Grade IV Malignant Glioma
Interventions: Drug: Gliadel (camustine), Radiation, Avastin (bevacizumab), Temodar (temozolomide)
Phase: Phase II
Recruiting
A Study of PX-866 in Patients With Glioblastoma Multiforme at Time of First Relapse or Progression
Conditions: Glioblastoma
Interventions: Drug: PX-866
Phase: Phase II
Recruiting
A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme
Conditions: Glioblastoma Multiforme
Interventions: Drug: MEDI-575
Phase: Phase II
Recruiting
Amgen 386 for Recurrent Glioblastoma
Conditions: Glioblastoma Multiforme
Interventions: Drug: Amgen 386, Drug: Bevacizumab
Phase: Phase II
Recruiting
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Conditions: Brain and Central Nervous System Tumors
Interventions: Drug: cediranib maleate, Drug: gefitinib, Genetic: gene expression analysis, Other: laboratory biomarker analysis
Phase: Phase II
Recruiting
Phase II Study of BKM120 for Subjects With Recurrent Glioblastoma
Conditions: Glioblastoma
Interventions: Drug: BKM120, Procedure: Surgery
Phase: Phase II
Recruiting
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
Conditions: Brain and Central Nervous System Tumors
Interventions: Drug: sunitinib malate, Genetic: gene expression analysis, Genetic: protein expression analysis, Other: laboratory biomarker analysis, Other: pharmacological study
Phase: Phase II
Recruiting
A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Conditions: Glioblastoma Multiforme
Interventions: Drug: bevacizumab, Drug: fotemustine
Phase: Phase II
Recruiting
Phase II Axitinib (AG-013736) in Elderly Glioblastoma Multiforme (GBM) Patients
Conditions: Glioblastoma Multiforme
Interventions: Drug: Axitinib, Radiation: Radiation Therapy
Phase: Phase II
Recruiting
Recruiting
Temodar (Temozolomide), Bevacizumab, Lithium and Radiation for High Grade Glioma
Conditions: Brain Cancer
Interventions: Drug: Temozolomide, bevacizumab, lithium, radiation
Phase: Phase II
Recruiting
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
Conditions: Acoustic Schwannoma, Grade III Meningioma, Adult Ependymoma, Adult Grade I Meningioma, Adult Grade II Meningioma, Adult Meningeal Hemangiopericytoma, Adult Papillary Meningioma, Neurofibromatosis Type 1, Neurofibromatosis Type 2, Recurrent Adult Brain Tumor
Interventions: Biological: bevacizumab
Phase: Phase II
Not yet recruiting
Bevacizumab and Lomustine in Treating Patients With Glioblastoma Multiforme in First Recurrence
Conditions: Brain and Central Nervous System Tumors, Cognitive/Functional Effects
Interventions: Biological: bevacizumab, Drug: lomustine, Genetic: DNA methylation analysis, Other: laboratory biomarker analysis, Procedure: cognitive assessment, Procedure: quality-of-life assessment
Phase: Phase II
Not yet recruiting
BIBF 1120 for Recurrent High-Grade Gliomas
Conditions: Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
Interventions: Drug: BIBF 1120
Phase: Phase II
Not yet recruiting
Avastin Plus Radiotherapy in Elderly Patients With Glioblastoma
Conditions: Glioblastoma
Interventions: Drug: Bevacizumab, Radiation: Radiation therapy
Phase: Phase II


Clinical Trial Data provided by http://www.clinicaltrials.gov.




Last updated February 29, 2012